Literature DB >> 15076146

Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease?

Jia L Zhuo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15076146      PMCID： PMC2277522          DOI： 10.1097/01.hjh.0000098211.37783.e7

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  26 in total

1.  The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine.

Authors:  S Sozzani; W Luini; M Molino; P Jílek; B Bottazzi; C Cerletti; K Matsushima; A Mantovani
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

2.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.

Authors:  Marta Ruiz-Ortega; Mónica Ruperez; Oscar Lorenzo; Vanesa Esteban; Julia Blanco; Sergio Mezzano; Jesus Egido
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

3.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions.

Authors:  S Ylä-Herttuala; B A Lipton; M E Rosenfeld; T Särkioja; T Yoshimura; E J Leonard; J L Witztum; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

4.  Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.

Authors:  L Wu; M Iwai; H Nakagami; Z Li; R Chen; J Suzuki; M Akishita; M de Gasparo; M Horiuchi
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

5.  Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes.

Authors:  T Yoshimura; E J Leonard
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.

Authors:  Thomas M Behr; Robert N Willette; Robert W Coatney; Marinela Berova; Christiane E Angermann; Karen Anderson; Jonathan D Sackner-Bernstein; Frank C Barone
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

Review 8.  The pathogenesis of atherosclerosis: atherogenesis and inflammation.

Authors:  J M Munro; R S Cotran
Journal:  Lab Invest       Date:  1988-03       Impact factor: 5.662

9.  Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

Authors:  Doris M Tham; Baby Martin-McNulty; Yi-xin Wang; Dennis W Wilson; Ronald Vergona; Mark E Sullivan; William Dole; John C Rutledge
Journal:  Physiol Genomics       Date:  2002-10-02       Impact factor: 3.107

Review 10.  Are there benefits to specific antihypertensive drug therapy?

Authors:  William C Cushman
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689
View more
  14 in total

Review 1.  Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.

Authors:  Brianne Ellis; Xiao C Li; Elisa Miguel-Qin; Victor Gu; Jia L Zhuo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  The Level of Monocyte Chemoattractant Protein-1 May Be Affected by Several Factors.

Authors:  Mustafa Gulgun
Journal:  Med Princ Pract       Date:  2018-05-20       Impact factor: 1.927

3.  Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells.

Authors:  Xiao C Li; Oscar A Carretero; Jia L Zhuo
Journal:  Biochem Pharmacol       Date:  2006-03-28       Impact factor: 5.858

Review 4.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

Review 5.  Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2007-03       Impact factor: 1.636

Review 6.  Nuclear factor-kappaB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-01       Impact factor: 2.894

7.  Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease.

Authors:  Y Bai; W Sigala; G R Adams; N D Vaziri
Journal:  Am J Nephrol       Date:  2008-09-17       Impact factor: 3.754

Review 8.  Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.

Authors:  Kailash N Pandey
Journal:  Physiol Genomics       Date:  2018-08-31       Impact factor: 3.107

9.  Intracellular ANG II directly induces in vitro transcription of TGF-beta1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Am J Physiol Cell Physiol       Date:  2008-02-06       Impact factor: 4.249

Review 10.  ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.

Authors:  T S Mohamed Saleem; K Bharani; K Gauthaman
Journal:  Open Access Emerg Med       Date:  2010-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.